Related Experiment Videos
[Macrolides in the treatment of children with Mediterranean spotted fever]
Antonio Cascio1, Claudia Colomba
1Istituto di Patoligia Infettiva e Virologia, Universita degli Studi di Palermo, Italy.
Abstract:
Till now there is not a gold standard therapy for Mediterranean spotted fever (MSF) in children. Standard treatment for MSF is the administration of tetracycline or chloramphenicol, however both these drugs can cause significant adverse effects in children (tetracyclines can cause staining of teeth, chloramphenicol severe hematological adverse events such as aplastic anemia, gray baby syndrome and hemolytic anemia in patients with the Mediterranean form of G6PD deficiency). We conducted two randomized clinical trials; the first compared clarithromycin versus chloramphenicol: mean time to defervescence was 36.7 +/- 18.1 h in the clarithromycin group and 47.1+/- 21.9 h in the chloramphenicol group (P= 0.047). The second trial compared clarithromycin versus azithromycin and did not show any statistically significant difference: mean time to defervescence was 46.2 +/- 36.4 h in the clarithromycin group and 39.3 +/- 31.3 h in the azithromycin group (P= 0.34). On the basis of these studies we think that clarithromycin and azithromycin could constitute an acceptable alternative to chloramphenicol and to tetracyclines for the treatment of MSF in children
Insights
Clarithromycin and azithromycin offer effective alternatives for treating Mediterranean spotted fever (MSF) in children, showing comparable or faster symptom resolution than traditional antibiotics like chloramphenicol.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
Background:
- Mediterranean spotted fever (MSF) lacks a definitive gold standard treatment in pediatric populations.
- Current standard therapies, tetracycline and chloramphenicol, carry significant risks for children, including dental staining and severe hematological adverse events.
Purpose of the Study:
- To evaluate the efficacy of clarithromycin and azithromycin as alternatives for pediatric MSF treatment.
- To compare the time to defervescence for clarithromycin versus chloramphenicol and clarithromycin versus azithromycin.
Main Methods:
- Two randomized clinical trials were conducted.
- Trial 1: Clarithromycin vs. Chloramphenicol for pediatric MSF.
- Trial 2: Clarithromycin vs. Azithromycin for pediatric MSF.
Main Results:
- Clarithromycin demonstrated a statistically significant shorter mean time to defervescence compared to chloramphenicol (36.7h vs 47.1h, P=0.047).
- No significant difference in time to defervescence was observed between clarithromycin and azithromycin (46.2h vs 39.3h, P=0.34).
Conclusions:
- Clarithromycin and azithromycin represent viable alternatives to tetracycline and chloramphenicol for treating MSF in children.
- These macrolide antibiotics may offer a safer therapeutic profile compared to established treatments.
Related Concept Videos
Rocky Mountain Spotted Fever
Antiprotozoal Agents
Inhibitors of Bacterial DNA Synthesis
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Endocarditis III: Medical Management
Tonsillitis II: Management